CSL share price: the Covid-19 impact examined

We look at how the coronavirus may impact Australia’s largest publicly listed company.

Not only did CSL last week reaffirm its already upgraded FY20 profit guidance – but at Tuesday’s closing price of $325 per share – the biotech behemoth sits only a shade off its 52-week high.

Indeed, when CSL first upgraded its full-year guidance in February, the company’s Chief Executive Paul Perreault proudly said: 'CSL is well positioned for sustainable growth.'

Sustainable growth, even in the face of global pandemic, apparently!

CSL share price: what analysts are saying

Of course, this is not to say that the coronavirus (Covid-19) situation doesn’t present a variety of unique challenges for the company.

CSL after all noted that the current situation presents a number of challenges to its plasma collection operations; and that the company expected modest delays across its capital projects and clinical trials.

UBS analysts, quantifying the impact of those challenges, estimate that CSL will see its plasma volumes contract by 5% over the next three to six month period. As a consequence of this, the company is also likely to see its 'IG/albumin volumes/sales' decline into the second half of FY21, argues UBS.

As a positive, the investment bank noted that, ‘plasma collection (as with whole blood donation) falls under the "essential services" banner, allowing those who want to donate an ability to do so.’

Even so, ‘With more US states implementing restrictions on people's movement, accessing collection centres may become more challenging for some donors.’

UBS currently has a Buy rating and a 12-month price target (PT) of $342.00 per share on CSL.

Yet even with those challenges in mind, the ever shareholder friendly biotech, stressed there was 'potential to accelerate activity post crisis to ensure no material change to original plan.'

The biotech even hit on one of the most talked up topics right now: liquidity. Here CSL assured investors it had plenty of it – specifically, around US$1.1 billion in available liquidity.

Like UBS, analysts from Macquarie argued that the impact of the coronavirus on CSL’s bottom-line is unlikely to be isolated to FY20. And though Macquarie downgraded its EPS forecasts for FY20 by just 1%, their analysts lowered CSL’s FY21e earnings forecasts by a more sizable 4%.

‘Given the lag between plasma collection and the manufacture of finished product, we see any COVID-19-related impacts over the next 3-6 months as primarily affecting earnings in FY21.’

Finally, and though the investment bank said that CSL boasts many favourable qualities, ‘we see the earnings risk associated with COVID-19/lower plasma volumes as skewed to the downside.’

Macquarie has a Neutral rating and a 12-month PT of $311.00 per share on CSL.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.


Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.